Joseph A. Fraietta

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (51)

Some patients cannot receive T cell therapies because their cells are unable to be manufactured. To address this limitation, we developed K562-based artificial antigen-presenting cells (aAPCs) expressing an OKT3-derived scFv for TCR stimulation, CD86 and 4-1BBL for costimulation, and membrane-bound IL-7 and IL-15Rα/IL-15 for cytokine support. From these aAPCs, we generated cell-derived nanoparticles (CDNPs) that accelerated T cell entry into the cell cycle compared with CD3/28-coated beads, enabling efficient concurrent activation and lentiviral transduction. CDNPs robustly expanded T cells from patients whose products could not be manufactured using standard approaches, and these CDNP-derived CAR T cells controlled tumors in humanized mouse models. In a phase I trial of patients with CD19⁺ malignancies (NCT04684563), cGMP-compatible CDNPs enabled streamlined 3-day manufacturing of IL-18–expressing CD19 CAR T cells, yielding higher cell recovery and durable clinical responses without unexpected toxicities, supporting CDNPs as a platform for commercial CAR T cell production.

Year:

2026

Comparison of Type I IFN gene expression in different CAR-T engineering approaches. (A-F) show volcano plots and a heatmap of gene expression in engineered CAR T-cells, with type I IFN genes highlighted in blue. These data represent different CAR-T engineering approaches, including: BRG1/BRM-associated factors (BAF) complex, Gata3, INO80 complex knockout (PMID35750052), BATF overexpression (PMID34282330), 4-1BB- versus CD28-based GD2 CAR activity (PMID 25939063) and 1xx CD19 CAR T-cells (GSE121226). These plots allow for a comparison of the levels of type I IFN gene expression in each of these different CAR-T engineering methods.

Year:

2025

EGR2 knockout enhances the long-term potency and memory function of CAR T-cells in vivo. A, Schematic of the tumor rechallenge experiments. B, Tumor growth after the first (left) and second (right) NALM6 challenges (Mann-Whitney test, n = 10). C, Mouse survival after high-dose second tumor challenge (Log-rank test). D, Tumor growth inhibition in a prostate cancer model using PSMA-targeting CAR T-cells with EGR2 or AAVS1 knockout (KO) compared to control CD19 CAR T-cells (19BBz). The tumor growth was monitored over time using caliper-based measurements in NSG mice (n = 8).

Year:

2025

Chromatin accessibility profiles for EGR2 knockout (KO) and AAVS1 knockout (AAVS1) CD8+ CAR T-cells. The table provides information on the locus mapping, p-value, average log2 fold change, percentage of cells, adjusted p-value, transcript ID, gene name, gene ID, gene biotype, region type, closest region, query region, and distance.

Year:

2025

Analysis of EGR2 and type I IFN pathway regulation in CAR T-cells. (A-C) ATAC-seq tracks of genes associated with dysfunction, type I IFN signaling, and memory differentiation are shown, with differentially accessible regions indicated. D, Heatmap showing expression of exhaustion genes in tonically signaling GD2 and functional CD19 naïve CD8+ CAR-T cells (GSE136891). E, Comparison of EGR2 and type I IFN gene signature scores in central memory CD8+ T-cells expressing a tonically signaling GD2 CAR and control CD19 CAR. CAR T-cells were generated using T-cells from a healthy donor (GSE136891). F, Top transcription factor co-expression signatures overexpressed in CD19 CAR T-cell products of CLL complete responders. G, Comparison of EGR2 and type I IFN signature scores in unstimulated CD19 CAR T-cell products from CLL patients (CR: complete response, PRTD: very good partial response, PR: conventional partial response, NR: no response). H, Comparison of type I IFN and EGR2 module scores in PSMA CAR T-cells from lymphodepleted prostate cancer patients, and their association with in vivo CAR T-cell proliferation and PSA decline.

Year:

2025

Marker gene expression in CAR T-cell clusters. A, Uniform manifold approximation and projection (UMAP) plot of AAVS1 and EGR2 knockout (KO) CAR T-cell samples is shown. B, UMAP plots showing expression levels of CD4 and CD8. C, Violin plot depicting expression of cluster-defining markers in CD4+ T-cells. D, Differentially expressed genes in IL7R+ versus CTLA4+ CD4+ T-cells. E, Violin plots showing expression levels of cluster-defining markers in CD8+ T-cells. F, Heatmap displaying differentially expressed genes between CD8+ cell clusters. G, Cell cycle scores mapped on UMAP plots.

Year:

2025

Epigenetic remodeling of CAR T-cells by EGR2 knockout and effect of type I IFN signaling on the development of memory and exhaustion. A, Volcano plots showing differentially accessible chromatin regions within genes between KLF2+ and MKI67+ CD8+ T-cells. B, Volcano plots depicting differentially accessible chromatin regions within genes between EGR2 and AAVS1 knockout (KO) CD8+ CAR T-cells. C, Representative contour plots showing frequencies of TIM3- and LAG3-expressing CD8+ CAR-T cells after exposure to IFNβ (1ng/mL) following chronic CAR stimulation. D, Proportions of CD27+ (left) or CD62L+ (right) CD8+ CAR-T cells after exposure to IFNβ. E, Representative contour plots showing frequencies of CD45RO+CD27+ CD8+ CAR-T cells after IFNAR blockade (Anifrolumab, 1µg/mL) during chronic antigen stimulation. F, Frequencies of TIM3+LAG3+ CD8+ CAR-T cells after IFNAR blockade. G, Cytolytic capacity of CAR T-cells as measured by normalized cell index kinetics using the xCELLigence real-time cytotoxicity assay following chronic stimulation with target cancer cells in the setting of either IFNβ or IFNAR blockade. H, Normalized cell index at 75 hours after challenge with target cancer cells. All experiments were conducted using healthy donor T-cells from independent donors (Mann-Whitney test, n = 4). *P

Year:

2025

Pathways regulated by EGR2 in CD8+ CAR T-cells. (A-C) Top pathways differentially expressed in EGR2 knockout CD8+ CAR-T cells compared to AAVS1 knockout CAR T-cells. Libraries used in this enrichment analysis: A, Reactome 2016. B, NCI-Nature Pathway Interaction Database 2015. C, ARCHS4 transcription factor (TF) co-expression.

Year:

2025

Gene expression and pathway enrichment analysis of CD8+ T cell clusters. A, Heatmap showing differentially expressed genes between memory-like KLF2+ and exhausted-like MKI67+ CD8+ T-cells. Gene signature scores related to cell cycle and clinical response are indicated on the top bars. B, Top downregulated GO biological processes in EGR2 compared to AAVS1 knockout CAR T-cells.

Year:

2025

Impact of EGR2 knockout on CD8+/CD4+ ratio and Th2 cytokine production in the setting of chronic tumor antigen stimulation. A, Comparison of CD8+/CD4+ ratio in control and EGR2 knockout (KO) CAR T-cells after chronic CAR stimulation. B, Th2 cytokine production by control and EGR2 KO CAR T-cells after 24 hours of CAR stimulation (Mann-Whitney test, n = 4). All experiments were performed using T-cells from three independent healthy donors. Panel B is representative data from one donor. *P

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (21)

Alfred Garfall

Assistant Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Edward A. Stadtmauer

University of Pennsylvania

UNITED STATES
View details

Shelley L. Berger

Director

University of Pennsylvania

UNITED STATES
View details

Dan Vogl

Associate Professor of Medicine

University of Pennsylvania

UNITED STATES
View details

Danielle C Pappas

-

UNITED STATES
View details

Saar I. Gill

University of Pennsylvania

UNITED STATES
View details

Elizabeth Hexner

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Carl H. June

Professor

University of Pennsylvania

UNITED STATES
View details

Gerald Linette

Professor

University of Pennsylvania

UNITED STATES
View details

Xiaowei Xu

Professor

University of Pennsylvania

UNITED STATES
View details

Nathan Singh

Assistant Professor

Washington University School of Medicine

UNITED STATES
View details

sandra susanibar adaniya

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Stephen Schuster

Professor, Clinician-Educator

Hospital of the University of Pennsylvania

UNITED STATES
View details

Beatriz M. Carreno

University of Pennsylvania

UNITED STATES
View details

Marco Ruella

PI

University of Pennsylvania

UNITED STATES
View details

Frederic D. Bushman

AO

University of Pennsylvania

UNITED STATES
View details

Sonia Guedan Carrio

Principal Investigator

Institut d'Investigacions Biomèdiques August Pi i Sunyer

SPAIN
View details

Naomi B Haas

PI

University of Pennsylvania

UNITED STATES
View details

James Riley

Professor

University of Pennsylvania

UNITED STATES
View details

Michael Milone

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Adam Cohen

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details